Nodular lymphocyte predominant Hodgkin lymphoma

Oncologist

Volumn 14, Issue 7, 2009, Pages 739-751

  Lee, Ian Alfred ^a   LaCasce, Ann S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Hodgkin lymphoma; LP cell; Nodular lymphocyte Hodgkin lymphoma

Indexed keywords

BLEOMYCIN A5; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; METHOTREXATE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

B CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; T LYMPHOCYTE; WORLD HEALTH ORGANIZATION;

FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; MALE; RETROSPECTIVE STUDIES;

EID: 68449094570     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0099     Document Type: Review

References (100)

1. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society, 2008:1-68.
2. Rosenthal SR. Significance of tissue lymphocytes in prognosis of lymphogranulomatosis. Arch Pathol 1936;21:628-646.
3. Jackson H, Parker F. Hodgkin's disease. I. General considerations. N Engl J Med 1944;230:108.
4. Jackson H, Parker F. Hodgkin's disease. II. Pathology. N Engl J Med 1944;231:35-44.
5. Lumb GD. Tumours of lymphoid tissue. Edinburgh and London: E. & S. Livingston, Ltd., 1954.
6. Hicks EB, Rappaport H, Winter WJ. Follicular lymphoma: A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956;9:792-821.
7. Smetana HF, Cohen BM. Mortality in relation to histologic type in Hodgkin's disease. Blood 1956;11:211-224.
8. Lukes RJ. Relationship of histologic features to clinical stages in Hodgkin's disease. Am J Roentgenol Radium Ther Nucl Med 1963;90: 944-955.
9. Lukes RJ. Hodgkin's disease. Prognosis and relationship of histologic features to clinical stage. JAMA 1964;190:914-915.
10. Dawson PJ, Harrison CV. A clinicopathological study of benign Hodgkin's disease. J Clin Pathol 1961;14:219-231.
11. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063-1083.
12. Lukes RJ, Craver LF, Hall TC et al. Report of the nomenclature committee. Cancer Res 1966;26:1311.
13. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
14. Hsu SM, Jaffe ES. Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol 1984;82:29-32.
15. Pinkus GS, Said JW. Hodgkin's disease, lymphocyte predominance type, nodular-a distinct entity? Unique staining profile for L&H variants of Reed-Sternberg cells defined by monoclonal antibodies to leukocyte common antigen, granulocyte-specific antigen, and B-cell-specific antigen. Am J Pathol 1985;118:1-6.
16. Pinkus GS, Said JW. Hodgkin's disease, lymphocyte predominance type, nodular-further evidence for a B cell derivation.L&Hvariants of Reed- Sternberg cells express L26, a pan B cell marker. Am J Pathol 1988;133: 211-217.
17. Pinkus GS, Thomas P, Said JW. Leu-M1-a marker for Reed-Sternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffinembedded tissues. Am J Pathol 1985;119:244-252. (Pubitemid 15040423)
18. Dorfman RF, Gatter KC, Pulford KA et al. An evaluation of the utility of anti-granulocyte and anti-leukocyte monoclonal antibodies in the diagnosis of Hodgkin's disease. Am J Pathol 1986;123:508-519.
19. Anagnostopoulos I, Hansmann ML, Franssila K et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889-1899. (Pubitemid 30661074)
20. Swerdlow SH, Campo E, Harris NL et al., eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. Geneva: World Health Organization, 2008.
21. Miettinen M, Franssila KO, Saxén E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983;51:2293-2300.
22. Hansmann ML, Zwingers T, Bôske A et al. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984;108:321-330. (Pubitemid 15211812)
23. Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988;318:214-219.
24. Borg-Grech A, Radford JA, Crowther D et al. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1989;7:1303-1309. (Pubitemid 19220133)
25. Mauch PM, Kalish LA, Kadin M et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993;71: 2062-2071. (Pubitemid 23068557)
26. Crennan E, D'Costa I, Liew KH et al. Lymphocyte predominant Hodgkin's disease: A clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys 1995;31: 333-337.
27. Pappa VI, Norton AJ, Gupta RK et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 1995;6:559-565.
28. de Jong D, Bosq J, MacLennan KA et al. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): Clinico-pathological characteristics and outcome of a rare entity. Ann Oncol 2006;17:141-145. (Pubitemid 43033854)
29. Sextro M, Diehl V, Franklin J et al. Lymphocyte predominant Hodgkin's disease-a workshop report. European Task Force on Lymphoma. Ann Oncol 1996;7(suppl 4):61-65.
30. Bodis S, KrausMD,PinkusGet al. Clinical presentation and outcome in lymphocyte- predominant Hodgkin's disease. J Clin Oncol 1997;15:3060-3066. (Pubitemid 27377497)
31. Orlandi E, Lazzarino M, Brusamolino E et al. Nodular lymphocyte predominance Hodgkin's disease: Long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997;26:359-368. (Pubitemid 27401920)
32. Franklin J, Tesch H, Hansmann ML et al. Lymphocyte predominant Hodgkin's disease: Pathology and clinical implication. Ann Oncol 1998; 9(suppl 5):S39-S44. (Pubitemid 29049116)
33. Diehl V, Sextro M, Franklin J et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776-783. (Pubitemid 29109305)
34. Feugier P, Labouyrie E, Djeridane M et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004;104:2675-2681. (Pubitemid 39434947)
35. Shimabukuro-Vornhagen A, Haverkamp H, Engert A et al. Lymphocyterich classical Hodgkin's lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005;23:5739-5745. (Pubitemid 46321305)
36. Wirth A, Yuen K, Barton M et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005;104:1221-1229. (Pubitemid 41278957)
37. Nogová L, Reineke T, Brillant C et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-439. (Pubitemid 351171696)
38. Mason DY, Banks PM, Chan J et al. Nodular lymphocyte predominance Hodgkin's disease. Adistinct clinicopathological entity. AmJ Surg Pathol 1994;18:526-530. (Pubitemid 2073089)
39. Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl 2005;(66):55-62.
40. Morton LM, Wang SS, Devesa SS et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
41. Ha CS, Kavadi V, Dimopoulos MA et al. Hodgkin's disease with lymphocyte predominance: Long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys 1999;43:329-334.
42. Falini B, Bigerna B, Pasqualucci L et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996;87:465-471. (Pubitemid 26030301)
43. Küppers R, Rajewsky K, Zhao M et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994;91: 10962-10966. (Pubitemid 24985070)
44. Delabie J, Tierens A, Wu G et al. Lymphocyte predominance Hodgkin's disease: Lineage and clonality determination using a single-cell assay. Blood 1994;84:3291-3298. (Pubitemid 24352889)
45. Marafioti T, Hummel M, Anagnostopoulos I et al. Origin of nodular lymphocyte- predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997;337:453-458. (Pubitemid 27333046)
46. Ohno T, Stribley JA, Wu G et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997;337:459-465. (Pubitemid 27333047)
47. Rd̈iger T, Gascoyne RD, Jaffe ES et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13(suppl 1):44-51.
48. Prakash S, Fountaine T, Raffeld M et al. IgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 2006;30:585-592. (Pubitemid 44265010)
49. Schmid C, Pan L, Diss T et al. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol 1991;139:701-707.
50. Stein H, Hansmann ML, Lennert K et al. Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin's disease of nodular subtype contain J chain. Am J Clin Pathol 1986;86:292-297. (Pubitemid 16023553)
51. Franke S, Wlodarska I, Maes B et al. Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. Blood 2001;97: 1845-1853. (Pubitemid 32217253)
52. Wlodarska I, Stul M, De Wolf-Peeters C et al. Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma. Haematologica 2004;89:965-972. (Pubitemid 39049905)
53. Renné C, Martín-Subero JI, Hansmann ML et al. Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition. J Mol Diagn 2005;7:352-356.
54. Marafioti T, Pozzobon M, Hansmann ML et al. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004;103:188-193. (Pubitemid 38029938)
55. Rahemtullah A, Reichard KK, Preffer FI et al. A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma. Am J Clin Pathol 2006;126:805-814. (Pubitemid 44707632)
56. Rahemtullah A, Harris NL, Dorn ME et al. Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma 2008;49:1870-1878.
57. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 1989;135:351-357. (Pubitemid 19240219)
58. Kadin ME, Liebowitz DN. Cytokines and cytokine receptors in Hodgkin's disease. In: Mauch P, Armitage JO, eds. Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins, 1999:139.
59. + T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol 2006;208:423-430.
60. Lennert K, Müller-Hermelink HK. [Lymphocytes and their functional forms-morphology, organization and immunologic significance]. Verh Anat Ges 1975;69:19-62. In German.
61. Bräuninger A, Yang W, Wacker HH et al. B-cell development in progressively transformed germinal centers: Similarities and differences compared with classical germinal centers and lymphocyte-predominant Hodgkin disease. Blood 2001;97:714-719. (Pubitemid 32113405)
62. Ferry JA, Zukerberg LR, Harris NL. Florid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin's disease. Am J Surg Pathol 1992;16:252-258.
63. Chang CC, Osipov V, Wheaton S et al. Follicular hyperplasia, follicular lysis, and progressive transformation of germinal centers. A sequential spectrum of morphologic evolution in lymphoid hyperplasia. Am J Clin Pathol 2003;120:322-326. (Pubitemid 37295102)
64. Poppema S, Kaiserling E, Lennert K. Hodgkin's disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres-a cytohistological study. Histopathology 1979;3:295-308. (Pubitemid 10232144)
65. Osborne BM, Butler JJ. Clinical implications of progressive transformation of germinal centers. Am J Surg Pathol 1984;8:725-733.
66. Osborne BM, Butler JJ, Gresik MV. Progressive transformation of germinal centers: Comparison of 23 pediatric patients to the adult population. Mod Pathol 1992;5:135-140.
67. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: Biology, diagnosis, and management. The Oncologist 2006;11:384-392.
68. Jaffe R, Bender B, Santamaria M et al. Segmental staining of the murine nephron by monoclonal antibodies directed against the GP-2 subunit of laminin. Lab Invest 1984;51:88-96. (Pubitemid 14053757)
69. Mirchandani I, Palutke M, Tabaczka P et al. B-cell lymphomas morphologically resembling T-cell lymphomas. Cancer 1985;56:1578-1583. (Pubitemid 15228505)
70. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988;12:433-443.
71. Delabie J, Vandenberghe E, Kennes C et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992;16:37-48.
72. Chittal SM, Brousset P, Voigt JJ et al. Large B-cell lymphoma rich in Tcells and simulating Hodgkin's disease. Histopathology 1991;19:211-220.
73. Bouabdallah R, Mounier N, Guettier C et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: A matched-control analysis. J Clin Oncol 2003;21:1271-1277. (Pubitemid 46606403)
74. Bennett MH, MacLennan KA, Vaughan Hudson G et al. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI:A 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991;2(suppl 2):83-92.
75. Greiner TC, Gascoyne RD, Anderson ME et al. Nodular lymphocytepredominant Hodgkin's disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 1996;88:657-666.
76. Wickert RS, Weisenburger DD, Tierens A et al. Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 1995;86:2312-2320.
77. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Hodgkin Disease/Lymphoma 2009. Version 2.2009. Available at http://www.nccn.org/professionals/physician-gls/PDF/hodgkins.pdf, accessed July 8, 2009.
78. Chera BS, Olivier K, Morris CG et al. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida. Am J Clin Oncol 2007;30:601-606. (Pubitemid 350307185)
79. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996;6: 225-242.
80. Schlembach PJ, Wilder RB, Jones D et al. Radiotherapy alone for lymphocyte- predominant Hodgkin's disease. Cancer J 2002;8:377-383.
81. Wilder RB, Schlembach PJ, Jones D et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 2002;94:1731-1738. (Pubitemid 34241111)
82. Nogová L, Reineke T, Eich HT et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005;16:1683-1687. (Pubitemid 41510144)
83. Tsai HK, Mauch PM. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol 2007;17:184-189.
84. Ekstrand BC, Lucas JB, Horwitz SM et al. Rituximab in lymphocytepredominant Hodgkin disease: Results of a phase 2 trial. Blood 2003;101: 4285-4289.
85. Keilholz U, Szelényi H, Siehl J et al. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono-clonal antibody) and interleukin-2. Leuk Lymphoma 1999;35:641-642. (Pubitemid 30015668)
86. Lush RJ, Jones SG, Haynes AP. Advanced-stage, chemorefractory lymphocyte- predominant Hodgkin's disease: Long-term follow-up of allografting and monoclonal antibody therapy. Br J Haematol 2001;114: 734-735.
87. + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101:420-424.
88. Schulz H, Rehwald U, Morschhauser F et al. Rituximab in relapsed lymphocyte- predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-111.
89. Murphy SB, Morgan ER, Katzenstein HM et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003;25:684-687. (Pubitemid 37087503)
90. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma- experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007;110:179-185. (Pubitemid 46986431)
91. Pellegrino B, Terrier-Lacombe MJ, Oberlin O et al. Lymphocyte-predominant Hodgkin's lymphoma in children: Therapeutic abstention after initial lymph node resection-a study of the French Society of Pediatric Oncology. J Clin Oncol 2003;21:2948-2952. (Pubitemid 46621846)
92. Karayalcin G, Behm FG, Gieser PW et al. Lymphocyte predominant Hodgkin disease: Clinico-pathologic features and results of treatment- the Pediatric Oncology Group experience. Med Pediatr Oncol 1997;29: 519-525. (Pubitemid 27419402)
93. Sandoval C, Venkateswaran L, Billups C et al. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002;24:269-273.
94. van Grotel M, Lam KH, de Man R et al. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma 2006;47:1504-1510. (Pubitemid 44364014)
95. Hall GW, Katzilakis N, Pinkerton CR et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma-a Children's Cancer and Leukaemia Group report. Br J Haematol 2007;138:761-768. (Pubitemid 47313220)
96. Vassilakopoulos TP, Angelopoulou MK, Pangalis GA. Treatment strategies for pediatric nodular lymphocyte predominant Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1450-1451. (Pubitemid 44364005)
97. Unal A, Sari I, Deniz K et al. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lymphoma 2005;46:1613-1617. (Pubitemid 41700995)
98. Shankar AG, Daw S, HallG W et al. Treatment of children and adolescents with early stage nodular lymphocyte predominant Hodgkin lymphoma with a low intensity short duration chemotherapy regimen [CVP]-on behalf of the EuroNet-PHL group. Blood 2006;208:2471.
99. Younes A, Romaguera J, Hagemeister F et al.Apilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314. (Pubitemid 36828455)
100. Fan Z, Natkunam Y, Bair E et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003;27:1346-1356. (Pubitemid 37185826)